Trivium Point Advisory LLC Boosts Holdings in Bristol Myers Squibb Company $BMY

Trivium Point Advisory LLC raised its position in Bristol Myers Squibb Company (NYSE:BMY) by 159.5% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 20,481 shares of the biopharmaceutical company’s stock after purchasing an additional 12,590 shares during the period. Trivium Point Advisory LLC’s holdings in Bristol Myers Squibb were worth $1,180,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the company. Vanguard Group Inc. raised its holdings in shares of Bristol Myers Squibb by 1.4% in the 4th quarter. Vanguard Group Inc. now owns 198,727,768 shares of the biopharmaceutical company’s stock valued at $10,719,376,000 after acquiring an additional 2,743,759 shares in the last quarter. State Street Corp grew its holdings in shares of Bristol Myers Squibb by 1.4% during the fourth quarter. State Street Corp now owns 97,980,438 shares of the biopharmaceutical company’s stock worth $5,285,065,000 after purchasing an additional 1,385,206 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Bristol Myers Squibb by 13.1% in the fourth quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company’s stock worth $2,837,026,000 after purchasing an additional 6,084,046 shares during the last quarter. Norges Bank bought a new position in shares of Bristol Myers Squibb in the fourth quarter worth approximately $1,947,272,000. Finally, AQR Capital Management LLC raised its stake in Bristol Myers Squibb by 172.6% in the fourth quarter. AQR Capital Management LLC now owns 25,796,905 shares of the biopharmaceutical company’s stock valued at $1,391,485,000 after purchasing an additional 16,332,924 shares in the last quarter. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Bristol Myers Squibb Stock Performance

Shares of BMY stock opened at $64.71 on Tuesday. The company has a market capitalization of $132.18 billion, a P/E ratio of 14.25, a PEG ratio of 0.17 and a beta of 0.22. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $68.10. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53. The stock has a 50 day moving average price of $59.75 and a two-hundred day moving average price of $59.06.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.60 by $0.44. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The firm had revenue of $12.97 billion for the quarter, compared to analysts’ expectations of $11.74 billion. During the same quarter last year, the business earned $1.46 earnings per share. The business’s revenue was up 5.7% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Analysts expect that Bristol Myers Squibb Company will post 6.95 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd were issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 3.9%. The ex-dividend date of this dividend was Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is 55.51%.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on BMY shares. JPMorgan Chase & Co. boosted their price target on shares of Bristol Myers Squibb from $67.00 to $73.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. Truist Financial restated a “buy” rating and set a $70.00 price objective (up from $65.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. Sanford C. Bernstein raised shares of Bristol Myers Squibb from a “market perform” rating to an “outperform” rating in a report on Wednesday, August 5th. UBS Group lowered shares of Bristol Myers Squibb from a “buy” rating to a “neutral” rating in a research report on Wednesday, August 5th. Finally, Wells Fargo & Company set a $65.00 target price on Bristol Myers Squibb and gave the company an “equal weight” rating in a research note on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Bristol Myers Squibb presently has an average rating of “Moderate Buy” and a consensus price target of $66.06.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.